Stock search

Ticker or company name

Solventum

SOLV · NYSE · Health Care

$88,65Down −0,43 (−0,48%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$15,1 bn
Div. yield
—
Year to date
+12,4%
52 weeks: $62,38$94,16

Ratio score

Not enough data for a score

The score is calculated when at least 6 of 10 metrics are known.

Key metrics

1 ✓ · 0 — · 1 ✕ · 8 n/a

n/aP/E vs its historyLess than 3 years of history96,3
P/E vs industryIndustry median 25,1 · +283%96,3
Forward P/E87% below the current one12,3
n/aRevenue growth, YoYNo data in the reports—
n/aEPS growth, YoYNo data in the reports—
n/aNet marginNo data in the reports—
n/aNet debt / EBITDANo data in the reports—
n/aFree cash flowNo data in the reports—
n/aShare count over a yearNo data in the reports—
n/aCash runwayNo data in the reports—

All metrics

MetricValue5-year medianIndustry median
P/E TTM96,3—25,1
Forward P/E12,3—16,2
PEGn/a—2,2
P/S1,9—2,2
EV/EBITDA20,5—17,3
P/FCF55,2—19,5
P/B3,1—3,4

Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 22 analysts

Buy
13
Hold
8
Sell
1

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20261,381,45Up +5,0%
Q2 20261,942,55Up +31,2%
Q1 20261,381,48Up +7,3%
Q4 20251,531,57Up +2,9%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: purchases $100 344 (1 person), no sales.

NameAmountSharesPrice
wendell amy mcbride10 Mar 2026 · open-market purchase$100 3441 475$68,03

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Health Care
Exchange
NYSE
Country
US
IPO date
26 Mar 2024

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
BAXBaxter International$25,5438would not consider—+5,3%−6,2%
ZBHZimmer Biomet$101,4167would watch26,0+7,0%9,0%
COOCooper Companies (The)$61,8889would consider20,9+4,7%13,5%
ALGNAlign Technology$165,9889would consider24,1+4,4%11,8%
DVADaVita$174,2272would consider11,9+6,4%6,5%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.